Novavax (NVAX) Projected to Post Quarterly Earnings on Wednesday

Novavax (NASDAQ:NVAX) is anticipated to release its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.3961) per share and revenue of $52.0610 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:30 AM ET.

Novavax (NASDAQ:NVAX) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.19. The firm had revenue of $118.90 million during the quarter, compared to analyst estimates of $79.81 million. Novavax had a negative return on equity of 14.82% and a negative net margin of 14.73%.Novavax’s revenue was down 79.0% compared to the same quarter last year. During the same period last year, the business posted $2.93 earnings per share. On average, analysts expect Novavax to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Novavax Trading Down 1.6%

NASDAQ:NVAX opened at $7.37 on Wednesday. Novavax has a 12-month low of $6.20 and a 12-month high of $11.97. The firm has a market cap of $1.21 billion, a PE ratio of -12.71 and a beta of 2.43. The stock has a fifty day moving average price of $9.10 and a 200 day moving average price of $9.00.

Institutional Trading of Novavax

A number of hedge funds and other institutional investors have recently bought and sold shares of NVAX. Legal & General Group Plc lifted its holdings in Novavax by 1.0% during the 3rd quarter. Legal & General Group Plc now owns 155,743 shares of the biopharmaceutical company’s stock worth $1,350,000 after buying an additional 1,529 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Novavax by 2.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 78,048 shares of the biopharmaceutical company’s stock worth $492,000 after acquiring an additional 1,718 shares in the last quarter. E Fund Management Co. Ltd. boosted its position in shares of Novavax by 9.0% during the 2nd quarter. E Fund Management Co. Ltd. now owns 28,280 shares of the biopharmaceutical company’s stock worth $178,000 after acquiring an additional 2,326 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Novavax by 2.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 104,562 shares of the biopharmaceutical company’s stock valued at $678,000 after acquiring an additional 2,750 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Novavax by 0.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,335,053 shares of the biopharmaceutical company’s stock valued at $8,972,000 after acquiring an additional 3,767 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on NVAX shares. Zacks Research raised Novavax from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 6th. Weiss Ratings downgraded Novavax from a “hold (c-)” rating to a “sell (d)” rating in a research report on Thursday, May 7th. BTIG Research restated a “buy” rating and set a $19.00 target price on shares of Novavax in a research note on Thursday, June 11th. Wall Street Zen raised shares of Novavax from a “sell” rating to a “hold” rating in a report on Sunday, May 31st. Finally, TD Cowen raised their target price on shares of Novavax from $8.00 to $9.00 and gave the company a “hold” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $13.00.

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.